全文获取类型
收费全文 | 159996篇 |
免费 | 14848篇 |
国内免费 | 8576篇 |
专业分类
耳鼻咽喉 | 1213篇 |
儿科学 | 2462篇 |
妇产科学 | 2059篇 |
基础医学 | 23509篇 |
口腔科学 | 2703篇 |
临床医学 | 19945篇 |
内科学 | 22827篇 |
皮肤病学 | 1734篇 |
神经病学 | 8378篇 |
特种医学 | 5203篇 |
外国民族医学 | 66篇 |
外科学 | 14889篇 |
综合类 | 23990篇 |
现状与发展 | 29篇 |
一般理论 | 49篇 |
预防医学 | 12615篇 |
眼科学 | 3777篇 |
药学 | 17440篇 |
122篇 | |
中国医学 | 7840篇 |
肿瘤学 | 12570篇 |
出版年
2024年 | 585篇 |
2023年 | 2322篇 |
2022年 | 5878篇 |
2021年 | 7584篇 |
2020年 | 5508篇 |
2019年 | 5047篇 |
2018年 | 5283篇 |
2017年 | 4791篇 |
2016年 | 4645篇 |
2015年 | 6694篇 |
2014年 | 8283篇 |
2013年 | 8369篇 |
2012年 | 11772篇 |
2011年 | 12493篇 |
2010年 | 8483篇 |
2009年 | 6933篇 |
2008年 | 8741篇 |
2007年 | 8874篇 |
2006年 | 8124篇 |
2005年 | 7468篇 |
2004年 | 6083篇 |
2003年 | 5892篇 |
2002年 | 5128篇 |
2001年 | 3547篇 |
2000年 | 3041篇 |
1999年 | 2752篇 |
1998年 | 1863篇 |
1997年 | 1972篇 |
1996年 | 1427篇 |
1995年 | 1355篇 |
1994年 | 1215篇 |
1993年 | 878篇 |
1992年 | 1044篇 |
1991年 | 956篇 |
1990年 | 868篇 |
1989年 | 798篇 |
1988年 | 726篇 |
1987年 | 612篇 |
1986年 | 590篇 |
1985年 | 485篇 |
1984年 | 440篇 |
1983年 | 374篇 |
1982年 | 340篇 |
1981年 | 315篇 |
1980年 | 272篇 |
1979年 | 261篇 |
1978年 | 240篇 |
1977年 | 259篇 |
1976年 | 237篇 |
1974年 | 194篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
32.
我们现在要尽量使这些治疗方法进入临床试验证明他们的可行性现在脊髓损伤的临床试验基金很有限,所以只有很少的这些治疗方法真正用于病人主要的制药厂开始对脊髓损伤治疗产生兴趣,我们现在还有很多工作要做,但是前景方向十分清楚,我们需要努力快速的工作。 相似文献
33.
V. E. Kataev O. I. Militsina I. Yu. Strobykina G. I. Kovylyaeva R. Z. Musin O. V. Fedorova G. L. Rusinov M. N. Zueva G. G. Mordovskoi A. G. Tolstikov 《Pharmaceutical Chemistry Journal》2006,40(9):473-475
Diesters based on isosteviol and dicarboxylic acids were synthesized and tested for antituberculous activity. Isosteviol and
some of its derivatives exhibit appreciable tuberculostatic properties in vitro, the activity being dependent on the length of the polymethylene spacer connecting two ent-beyeran fragments. The mechanism of the antituberculous action of isosteviol derivatives are discussed.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 9, pp. 12–13, September, 2006. 相似文献
34.
35.
36.
37.
Rapid growth in biomedical research coupled with dramatic advancement in biotechnology has significantly improved our understanding of the molecular basis involving cancer development and progression. This improvement has led to the discovery of new molecular markers for cancer diagnosis and prognosis as well as new molecular targets for cancer treatment and intervention. Continuous emergence of some new developing area in molecular profiling, new therapeutic agents, tissue microenvironment and systems biology have made significant progress in clinical oncology. Clinical research and investigation that focus on these new developments have begun to show exciting results that indicate future promises in improving patient management and survival. 相似文献
38.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
39.
The influence of chronic administration of a dry cleared extract of Glycyrrhiza glabra (DCEG) containing flavonoids on the behavioral status and learning of intact and ovariectomized adult female rats has been
studied. The DCEG preparation was administered in low (0.5 mg/kg, i.p.) and high (5.0 mg/kg, i.p.) daily doses over a period
of 14 days and the results were evaluated on the passive avoidance situation model and in the open field test. It was established
that the chronic administration of DCEG in both low and high doses produced correction of the passive avoidance performance
in ovariectomized female rats. The administration of DCEG in a low dose also positively influenced the structure of purposeful
behavior of females with deficiency of estrogens.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 39, No. 8, pp. 27 – 29, August, 2005. 相似文献
40.